These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 19276794)

  • 1. Antiretroviral drug susceptibility among drug-naive adults with recent HIV infection in Rakai, Uganda.
    Eshleman SH; Laeyendecker O; Parkin N; Huang W; Chappey C; Paquet AC; Serwadda D; Reynolds SJ; Kiwanuka N; Quinn TC; Gray R; Wawer M
    AIDS; 2009 Apr; 23(7):845-52. PubMed ID: 19276794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1: clinical, phenotypic and genotypic correlates.
    Whitcomb JM; Huang W; Limoli K; Paxinos E; Wrin T; Skowron G; Deeks SG; Bates M; Hellmann NS; Petropoulos CJ
    AIDS; 2002 Oct; 16(15):F41-7. PubMed ID: 12370521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiretroviral drug susceptibility among HIV-infected adults failing antiretroviral therapy in Rakai, Uganda.
    Reynolds SJ; Laeyendecker O; Nakigozi G; Gallant JE; Huang W; Hudelson SE; Quinn TC; Newell K; Serwadda D; Gray RH; Wawer MJ; Eshleman SH
    AIDS Res Hum Retroviruses; 2012 Dec; 28(12):1739-44. PubMed ID: 22443282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of phenotypic and genotypic resistance to antiretroviral therapy in the UNAIDS HIV Drug Access Initiative--Uganda.
    Weidle PJ; Downing R; Sozi C; Mwebaze R; Rukundo G; Malamba S; Respess R; Hertogs K; Larder B; Ochola D; Mermin J; Samb B; Lackritz E
    AIDS; 2003 Jul; 17 Suppl 3():S39-48. PubMed ID: 14565608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phenotypic hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in treatment-experienced HIV-infected patients: impact on virological response to efavirenz-based therapy.
    Shulman N; Zolopa AR; Passaro D; Shafer RW; Huang W; Katzenstein D; Israelski DM; Hellmann N; Petropoulos C; Whitcomb J
    AIDS; 2001 Jun; 15(9):1125-32. PubMed ID: 11416714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV-1 reverse transcriptase and protease resistance mutations selected during 16-72 weeks of therapy in isolates from antiretroviral therapy-experienced patients receiving abacavir/efavirenz/amprenavir in the CNA2007 study.
    Ait-Khaled M; Rakik A; Griffin P; Stone C; Richards N; Thomas D; Falloon J; Tisdale M;
    Antivir Ther; 2003 Apr; 8(2):111-20. PubMed ID: 12741623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of drug resistance in children receiving antiretroviral therapy for treatment of HIV-1 infection in Uganda.
    Towler WI; Barlow-Mosha L; Church JD; Bagenda D; Ajuna P; Mubiru M; Musoke P; Eshleman SH
    AIDS Res Hum Retroviruses; 2010 May; 26(5):563-8. PubMed ID: 20455758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Virological significance, prevalence and genetic basis of hypersusceptibility to nonnucleoside reverse transcriptase inhibitors.
    Tachedjian G; Mijch A
    Sex Health; 2004; 1(2):81-9. PubMed ID: 16334989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Investigation of HIV-1 primary drug resistance mutations in antiretroviral therapy-naive cases].
    Yalçınkaya T; Köse S
    Mikrobiyol Bul; 2014 Oct; 48(4):585-95. PubMed ID: 25492654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance-associated mutations and polymorphisms in NNRTI-naïve HIV-infected patients.
    Clevenbergh P; Cua E; Dam E; Durant J; Schmit JC; Boulme R; Cottalorda J; Beyou A; Schapiro JM; Clavel F; Dellamonica P
    HIV Clin Trials; 2002; 3(1):36-44. PubMed ID: 11819184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance.
    Yap SH; Sheen CW; Fahey J; Zanin M; Tyssen D; Lima VD; Wynhoven B; Kuiper M; Sluis-Cremer N; Harrigan PR; Tachedjian G
    PLoS Med; 2007 Dec; 4(12):e335. PubMed ID: 18052601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of antiretroviral drug resistance and resistance-associated mutations in antiretroviral therapy-naïve HIV-infected individuals from 40 United States cities.
    Ross L; Lim ML; Liao Q; Wine B; Rodriguez AE; Weinberg W; Shaefer M
    HIV Clin Trials; 2007; 8(1):1-8. PubMed ID: 17434843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reverse transcriptase mutations 118I, 208Y, and 215Y cause HIV-1 hypersusceptibility to non-nucleoside reverse transcriptase inhibitors.
    Clark SA; Shulman NS; Bosch RJ; Mellors JW
    AIDS; 2006 Apr; 20(7):981-4. PubMed ID: 16603849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of laboratory methods for analysis of non-nucleoside reverse transcriptase inhibitor resistance in Ugandan infants.
    Church JD; Huang W; Parkin N; Marlowe N; Guay LA; Omer SB; Musoke P; Jackson JB; Eshleman SH
    AIDS Res Hum Retroviruses; 2009 Jul; 25(7):657-63. PubMed ID: 19621988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy.
    Hosseinipour MC; van Oosterhout JJ; Weigel R; Phiri S; Kamwendo D; Parkin N; Fiscus SA; Nelson JA; Eron JJ; Kumwenda J
    AIDS; 2009 Jun; 23(9):1127-34. PubMed ID: 19417582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiretroviral resistance and genetic diversity of human immunodeficiency virus type 1 isolates from the Federal District, Central Brazil.
    Cerqueira DM; Amorim RM; Silva RR; Camara GN; Brígido MM; Martins CR
    Mem Inst Oswaldo Cruz; 2004 Dec; 99(8):877-82. PubMed ID: 15761606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: a bayesian analysis.
    Ngo-Giang-Huong N; Jourdain G; Amzal B; Sang-a-gad P; Lertkoonalak R; Eiamsirikit N; Tansuphasawasdikul S; Buranawanitchakorn Y; Yutthakasemsunt N; Mekviwattanawong S; McIntosh K; Lallemant M;
    PLoS One; 2011; 6(11):e27427. PubMed ID: 22132100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phenotypic drug resistance patterns in subtype A HIV-1 clones with nonnucleoside reverse transcriptase resistance mutations.
    Eshleman SH; Jones D; Galovich J; Paxinos EE; Petropoulos CJ; Jackson JB; Parkin N
    AIDS Res Hum Retroviruses; 2006 Mar; 22(3):289-93. PubMed ID: 16545016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phenotype, Genotype, and Drug Resistance in Subtype C HIV-1 Infection.
    Derache A; Wallis CL; Vardhanabhuti S; Bartlett J; Kumarasamy N; Katzenstein D
    J Infect Dis; 2016 Jan; 213(2):250-6. PubMed ID: 26175454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.